Stock Ratings / Health Care / RCEL / insiders

SENS (38) ANGO (50) DCTH (57) SGHT (38) ⌘ Pro Terminal →

Avita Medical Inc. (RCEL) Insider, 13F Hedge Fund & Politician Buy/Sell Thermometer

$16.71 +1.27% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $16.72

Avita Medical Inc. (RCEL) carries a Roarable Rating of D (Sell) with 44/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record Warning: Scores below 50 (44/100 · D) historically underperformed SPY in 71% of rolling 90-day windows →

ROARABLE D • SELL / AVOID Cap $516.8M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $16.72 (+0.04%)🧬 Dilution Drag (+2.48% YoY Shares)⚙️ Cash Engine: 8/20 (D-) • 0% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record Warning: Scores below 50 (44/100 · D) historically underperformed SPY in 71% of rolling 90-day windows (-6.5% avg 90D alpha vs SPY • 29.0% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERSELL / AVOID • D

2-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D- · Rk D+

Each axis scored 0–20

12M PRICE TARGET CONE-6.3% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for RCEL)Realized 20D OHLCV Swing Band: ±12.5%

Deterministic 5-Pillar Attribution (44/100 Composite)

🔍 WHY RCEL SCORES 44/100 (D) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: Whale & Options Positioning+12/20 pts (27% of score)

20D Institutional Volume Accumulation (±12.5% realized swing band)

▲ #2 Bullish Driver: SEC 10-K Forensic Risk+11/20 pts (25% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 4/9

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)

Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade E$13.21-1.3% Next Q

Q2 (-2Q)

Grade E$13.04+18.9% Next Q

Q3 (-1Q)

Grade D$15.51+7.7% Next Q

Current

Grade D$16.71-6.5% Hist 90D α

Trajectory: E (36) → D (44)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a RCEL Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While RCEL currently carries a cautious 44/100 (D) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($12.21) and Max Pain ($17.55) forces dealer call-delta covering toward $18.48.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $RCEL• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “RCEL Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 44%NO 56%Trade / Inspect Odds →

SEC FORM 4 × 13F HEDGE FUNDS × CONGRESSIONAL STOCK ACT

RCEL Smart-Money Thermometer: NET EXECUTIVE TRIMMING / PROFIT-TAKING

Explore All 13F & Congress Whales →

▲ Disclosed Buys: 0 ($0)▼ Disclosed Sales: 0 ($0)

Wide-Open SEC Form 4, 13F & Congressional Disclosure Ledger (RCEL)

No recent open-market Form 4 cluster sales or emergency dumps flagged on RCEL. Visit the Global 13F & Congressional Whale Ledger for cross-market smart-money filings.

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring RCEL)

✓Walkthrough of RCEL's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

RCEL // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +286.81%▲ RESISTANCE BREAKOUT

2026-10-30O $16.54H $16.71L $15.24C $16.71VOL 596.6K

RES: $14.33SUP: $5.55SMA50: $12.21SMA200: $6.55

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

RCEL Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 RCEL Butterfly Map → + Track RCEL →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. +11.5% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on RCEL today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for RCEL. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for RCEL today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (RCEL)

Health Care Rank #506 of 1016 ⚔️ SENS vs RCEL Full Matrix →

1. Head-to-Head Health Care Peer Comparison (RCEL vs. SENS, ANGO, DCTH, SGHT)

Industry: Medical/Dental Instruments (120 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Avita Medical Inc. (RCEL) ranks #506 by composite RQD confidence (44/100, grade D) and #442 by equity capitalization ($516.8M). Within this direct 5-issuer industry benchmark cohort, RCEL leads on earnings valuation at N/A trailing P/E, while DCTH leads on capital efficiency and profitability with 0.8% ROIC and 86.2% gross margin. DCTH currently holds the highest overall quantitative score in the immediate peer group at 57/100 (D+) compared with RCEL at 44/100 (D).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
RCEL ACTIVE Avita Medical Inc.	D	44/100	—	82.1%	-35.0%	+1.27%	$516.8M	Benchmark Subject
SENS Senseonics Holdings Inc.	D-	38/100	—	44.7%	-35.0%	+4.39%	$515.5M	/sens-vs-rcel →
ANGO AngioDynamics Inc.	D	50/100	—	54.6%	-23.4%	+1.81%	$519.4M	/ango-vs-rcel →
DCTH Delcath Systems Inc.	D+	57/100	—	86.2%	0.8%	-1.48%	$508.0M	/dcth-vs-rcel →
SGHT Sight Sciences Inc.	D-	38/100	—	86.2%	-35.0%	+3.57%	$527.2M	/sght-vs-rcel →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001762303

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Avita Medical Inc. (RCEL) reported GAAP revenue of $71.6M (+11.5% vs. FY2024 revenue of $64.3M , and +42.8% cumulative change since FY2023) , GAAP net income of -$48.6M, operating cash flow of -$31.2M, and free cash flow of -$32.2M (+44.5% YoY). On the balance sheet, RCEL closed FY2025 with $56.4M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 4/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$71.6M	-$48.6M	-$31.2M	-$32.2M	$56.4M	$0
FY2024 (FY)	2024-12-31	$64.3M	-$61.8M	-$48.9M	-$58.1M	$79.7M	$42.2M
FY2023 (FY)	2023-12-31	$50.1M	-$35.4M	-$38.0M	-$38.0M	—	—

3. RCEL Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is RCEL stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, Avita Medical Inc. (NASDAQ: RCEL) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 44/100 at a spot price of $16.71 (+1.27% 1D, market cap $516.8M). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 12/20, Executive Insider Alignment 11/20, FRED Macro Regime Fit 10/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, RCEL ranks #506 in composite RQD confidence.

How does RCEL compare to SENS and ANGO in the Health Care sector?

Within the Health Care sector (Medical/Dental Instruments), RCEL carries a Roarable D (44/100 RQD), trailing P/E of N/A, gross margin of 82.1%, and ROIC of -35.0%. By comparison, SENS (Senseonics Holdings Inc.) holds a D- grade (38/100 RQD, P/E N/A, ROIC -35.0%, cap $515.5M) and ANGO (AngioDynamics Inc.) posts a D grade (50/100 RQD, P/E N/A, ROIC -23.4%, cap $519.4M). Among the 5-stock peer group, RCEL leads on earnings multiple (N/A) while DCTH leads on capital efficiency (0.8% ROIC).

What are the biggest fundamental strengths and SEC risk factors for RCEL?

Per RCEL's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001762303), Avita Medical Inc. generated $71.6M in revenue (+11.5% YoY), -$48.6M in net income, and -$32.2M in free cash flow against $56.4M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is RCEL trading relative to its 50-day, 200-day, and 52-week technical levels?

RCEL last traded at $16.71 (+1.27% on volume of 312,972 shares), positioning the stock +36.86% above its 50-day simple moving average ($12.21) and +155.11% above its 200-day simple moving average ($6.55). Across its 52-week range of $3.22 to $16.90, RCEL sits at the 98.6% percentile with a 14-day RSI of 66.2 (BULLISH MOMENTUM) and an implied next-earnings move of ±12.5% ($14.62 to $18.80).

RCEL Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

Are RCEL insiders and hedge funds buying or selling?

Roarable's SEC Form 4 and 13F Whale Thermometer currently classifies RCEL leadership and institutional positioning as: NET EXECUTIVE TRIMMING / PROFIT-TAKING.

Direct Sub-Reports: RCEL RQD Cockpit RCEL 12M Forecast RCEL Earnings & Move RCEL Dividends & DRIP RCEL Insiders & 13F RCEL Whale Options RCEL Profit Sankey RCEL News & Why